| 1374 |
National Cancer Institute |
Html |
en |
Stomach (Gastric) Cancer Screening (PDQ®)–Health Professional Version |
For stomach (gastric) cancer, there is no standard or routine screening test for the general U.S. population. Review the evidence on the benefits and harms of screening for gastric cancer using barium-meal photofluorography, gastric endoscopy, or serum pepsinogen in this expert-reviewed summary. |
| immigrant ethnic populations | 0.555723 |
| routine screening | 0.545026 |
| population-based screening | 0.55023 |
| major type | 0.538572 |
| gastric adenomatous polyps | 0.695374 |
| versus unscreened individuals | 0.55595 |
| atrophic gastritis | 0.615129 |
| H. pylori | 0.564647 |
| distal stomach | 0.538456 |
| gastric cancer worldwide | 0.720749 |
| gastric carcinoma. | 0.66881 |
| diffuse type. | 0.56645 |
| pepsinogen levels | 0.550707 |
| gastric mortality | 0.684336 |
| gastric endoscopy | 0.658667 |
| sporadic gastric adenomas | 0.698707 |
| Low serum pepsinogen | 0.556585 |
| case-control studies | 0.567568 |
| coincident decrease | 0.54268 |
| gastric cancer mortality | 0.786779 |
| intestinal metaplasia | 0.542939 |
| tissue gastric lymphoma | 0.689624 |
| gastric lymphoma. | 0.665709 |
| screening study | 0.547045 |
| duodenal ulcer disease | 0.55893 |
|
| standard cut-off values | 0.552573 |
| familial adenomatous polyposis | 0.560734 |
| single referral center | 0.552547 |
| gastric body | 0.665835 |
| proton pump inhibitors | 0.55184 |
| common cancer | 0.560082 |
| national program | 0.560036 |
| screening program | 0.548065 |
| noncardia gastric carcinoma | 0.695412 |
| classifies H. pylori | 0.563321 |
| diffuse type | 0.542605 |
| gastric carcinoma | 0.707449 |
| indigestion change pepsinogen | 0.555323 |
| gastric cancer | 0.921375 |
| type gastric cancer | 0.702788 |
| intestinal type | 0.629856 |
| striking decrease | 0.543352 |
| pernicious anemia | 0.567146 |
| chronic atrophic gastritis | 0.574769 |
| gastric cancer. | 0.695414 |
| stomach cancer | 0.550691 |
| nonpolyposis colon cancer | 0.578666 |
| twofold decrease | 0.54109 |
| Gastric adenocarcinomas | 0.6758 |
|
CLICK HERE |
| 1423 |
National Cancer Institute |
Html |
en |
Oral Cavity and Oropharyngeal Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing cancer of the lip or mouth and about approaches that may help in the prevention of this disease. |
| large cohort study | 0.376766 |
| oral cavity accounts | 0.552607 |
| Papua New Guinea | 0.380571 |
| French Guiana | 0.34684 |
| United States | 0.44201 |
| age-adjusted incidence | 0.362072 |
| 100,000 | 0.359624 |
| areca nut. | 0.346627 |
| high alcohol intake | 0.39156 |
| epidemiologic studies | 0.378316 |
| oropharyngeal cancers | 0.387229 |
| 5-year survival rate | 0.495328 |
| oropharyngeal cancer. | 0.45765 |
| personal history | 0.348827 |
| Human papillomavirus | 0.350206 |
| oral cavity cancer | 0.797428 |
| future primary cancer | 0.407597 |
| betel quid | 0.499314 |
| tobacco | 0.395457 |
| stage-specific survival rates | 0.38041 |
| important risk factor | 0.379095 |
| World Standard Population | 0.382887 |
| regional lymph node | 0.379129 |
| U.S. incidence | 0.3611 |
|
| worldwide incidence rate | 0.411302 |
| Squamous cell carcinoma | 0.382371 |
| risk factors | 0.357771 |
| elevated risk | 0.400796 |
| betel-quid chewing | 0.354181 |
| distinct diseases | 0.351665 |
| relative risk | 0.346929 |
| mortality rate | 0.410597 |
| common pharyngeal cancer. | 0.386214 |
| pharynx cancer | 0.364625 |
| persons | 0.372394 |
| Gutka chewing | 0.349427 |
| commonly available forms | 0.391505 |
| smokeless tobacco | 0.374103 |
| oral mucosal | 0.411667 |
| high risk | 0.355532 |
| neck region | 0.347305 |
| oral cavity | 0.982405 |
| oropharyngeal cancer | 0.482897 |
| mortality estimates | 0.39101 |
| added tobacco | 0.357539 |
| betel leaf | 0.365996 |
| mortality rates | 0.364344 |
|
CLICK HERE |
| 1461 |
National Cancer Institute |
Html |
en |
Vaginal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of vaginal cancer. |
| ongoing clinical trials | 0.85552 |
| long time span | 0.761526 |
| vaginal carcinoma | 0.951107 |
| vaginal wall involvement | 0.883409 |
| prior hysterectomy | 0.778571 |
| vaginal cancer | 0.818887 |
| vaginal cancer. | 0.807751 |
| available staging tests | 0.778942 |
| upper vaginal lesions | 0.893311 |
| Regional lymph nodes | 0.757227 |
| concurrent chemotherapy | 0.764946 |
| clear cell carcinomas | 0.789213 |
| cervical cancer | 0.899035 |
| Vaginal adenosis | 0.826312 |
| vaginal carcinomas | 0.846251 |
| vaginal SCC patients | 0.90084 |
| treatment approaches | 0.767338 |
| women | 0.767592 |
| treatment | 0.85362 |
| AJCC staging system. | 0.759072 |
| vaginal vault | 0.831513 |
| case series | 0.90433 |
| utero DES exposure | 0.803909 |
| apical vagina | 0.754218 |
| vaginal intraepithelial neoplasia | 0.874302 |
|
| external-beam radiation | 0.754266 |
| treatment planning | 0.776769 |
| clear cell carcinoma | 0.966645 |
| clear cell adenocarcinoma | 0.790722 |
| vaginal cancers | 0.837225 |
| local modality therapies | 0.783604 |
| cervical cancer management | 0.790278 |
| noninvasive squamous cell | 0.774465 |
| relative efficacy | 0.761447 |
| Gy tumor dose | 0.754907 |
| vaginal clear cell | 0.868627 |
| disease | 0.778359 |
| precise staging criteria | 0.772344 |
| local control | 0.818953 |
| utero exposure | 0.878366 |
| Early stage tumors | 0.815533 |
| cervical intraepithelial neoplasia | 0.792254 |
| small case series | 0.758482 |
| insufficient dose penetration | 0.75402 |
| American Joint Committee | 0.782817 |
| locally advanced tumors | 0.766917 |
| Cervical Cancer Treatment | 0.817322 |
| surgical treatment options | 0.788171 |
| standard treatment | 0.795403 |
|
CLICK HERE |
| 1659 |
National Cancer Institute |
Html |
en |
Genetics of Skin Cancer (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the genetics of skin cancer — basal cell carcinoma, squamous cell carcinoma, and melanoma — including information about specific gene mutations and related cancer syndromes. The summary also contains information about interventions that may influence the risk of developing skin cancer in individuals who may be genetically susceptible to these syndromes. |
| nevoid BCC syndrome | 0.361131 |
| skin cancer | 0.445517 |
| subsequent basal cell | 0.405637 |
| cell types | 0.363322 |
| inbasal cell carcinoma | 0.372942 |
| cell naevus syndrome | 0.392978 |
| infundibulocystic basal cell | 0.393823 |
| multiple basal cell | 0.462541 |
| nevoid basal-cell carcinoma | 0.367205 |
| basal-cell carcinoma syndrome | 0.380703 |
| naevoid basal cell | 0.446514 |
| cell nevus syndrome | 0.483609 |
| keratocystic odontogenic tumors | 0.361624 |
| nevoid basal cell | 0.773092 |
| multiple nevoid basal | 0.40348 |
| carcinoma syndrome lead | 0.369766 |
| Br J Dermatol | 0.370287 |
| basal cell tumor | 0.411053 |
| basal cell keratinocytes | 0.422712 |
| basal cell carcinoma | 0.952732 |
| et al. | 0.483994 |
| human basal cell | 0.406014 |
| Arch Dermatol | 0.379242 |
| basal cell skin | 0.440681 |
| cell nevoid syndrome | 0.373946 |
|
| cell skin cancer | 0.406713 |
| PUBMED Abstract | 0.466137 |
| Eur Acad Dermatol | 0.357296 |
| pathogenic variants | 0.416348 |
| familial basal cell | 0.406823 |
| sporadic basal cell | 0.406156 |
| squamous cell skin | 0.357805 |
| gorlin syndrome | 0.402395 |
| BASAL CELL TUMOURS | 0.39834 |
| Med Genet | 0.412537 |
| Abstract | 0.519599 |
| invasive basal cell | 0.401542 |
| basal cell nevus | 0.538871 |
| basal keratinocytes | 0.391532 |
| germline pathogenic variants | 0.357761 |
| basal cell naevus | 0.432813 |
| cell carcinoma syndrome | 0.750335 |
| basal cell carcinomas | 0.628359 |
| basal cell cancer | 0.436245 |
| nonmelanoma skin cancer | 0.368108 |
| Hum Genet | 0.375007 |
| basal layer | 0.373145 |
| Acad Dermatol | 0.401088 |
| early-onset basal cell | 0.406919 |
|
CLICK HERE |
| 1827 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia linfocítica crónica (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfocítica crónica. |
| genetic features predict | 0.402765 |
| Davis Z | 0.402966 |
| Exp Med | 0.403766 |
| with chronic lymphocytic | 0.453469 |
| B-cell chronic lymphocytic | 0.404152 |
| Hamblin TJ | 0.403993 |
| Montserrat E | 0.403191 |
| patients with rai | 0.4028 |
| lymphocytic leukemia reveals | 0.403683 |
| O'Brien S | 0.403439 |
| Keating MJ | 0.403308 |
| granular lymphocytes | 0.404274 |
| patients with chronic | 0.453881 |
| terapia inmediata versus | 0.402689 |
| CD38 expression | 0.404463 |
| ZAP-70 expression | 0.403246 |
| La LLC | 0.412195 |
| cell chronic lymphocytic | 0.409866 |
| Lymphocytic Leukemia updating | 0.403993 |
| patients with | 0.466989 |
| early-stage chronic lymphocytic | 0.403314 |
| gene expression | 0.402974 |
| Shanafelt TD | 0.404951 |
| International Workshop | 0.403274 |
| leukemia treated with | 0.403613 |
|
| granular lymphocyte leukemia | 0.40409 |
| versus clorambucilo | 0.403972 |
| French Cooperative Group | 0.402864 |
| monoclonal b-cell lymphocytosis | 0.404973 |
| Loughran TP Jr | 0.403102 |
| prognostic features | 0.40312 |
| leukemia with | 0.405469 |
| immunoglobulin mutation genotype | 0.402773 |
| lymphocytic leukemia from | 0.403953 |
| high-risk features such | 0.40263 |
| chronic lymphoid leukemia | 0.404328 |
| granular lymphocytic leukemia | 0.403581 |
| VH mutation status | 0.402969 |
| T-cell chronic lymphocytic | 0.403416 |
| large granular lymphocyte | 0.403546 |
| Clin Oncol | 0.457605 |
| Catovsky D | 0.410385 |
| mutation status | 0.410696 |
| chronic lymphocytic leukemia | 0.989679 |
| chronic lymphocytic leukaemia | 0.467178 |
| with chronic lymphoid | 0.403309 |
| lymphocyte leukemia with | 0.403276 |
| following chemoimmunotherapy with | 0.404045 |
| features such as | 0.402637 |
|
CLICK HERE |
| 1913 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de testículo (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de testículo. |
| estadio is | 0.441617 |
| siguientes procedimientos | 0.287311 |
| células madre | 0.729809 |
| orquiectomÃa inguinal | 0.910567 |
| Testicular Cancer | 0.25752 |
| Pronóstico intermedio | 0.226624 |
| tubos minúsculos | 0.238436 |
| menor frecuencia | 0.216803 |
| rayos x | 0.232109 |
| sistema urinario masculino | 0.265452 |
| Pronóstico adverso | 0.227528 |
| estadio ib | 0.342087 |
| estadio ia | 0.340936 |
| largo plazo | 0.339676 |
| enlace drugs approved | 0.310101 |
| ondas sonoras | 0.236752 |
| National Cancer Institute | 0.216079 |
|
| siguientes riesgos | 0.21354 |
| Instituto Nacional | 0.230763 |
| estadio iiia | 0.333884 |
| PDQ Tratamiento | 0.233897 |
| estadio iiic | 0.330798 |
| estadio iia | 0.338825 |
| estadio iic | 0.337012 |
| coriónica humana beta | 0.516427 |
| Physician Data Query | 0.263764 |
| distinta manera | 0.239745 |
| Antecedentes familiares | 0.232829 |
| túbulos minúsculos | 0.234263 |
| glándulas sexuales masculinas | 0.271775 |
| ganglios linfáticos distantes | 0.736212 |
| toma imágenes | 0.223821 |
| siguientes pruebas | 0.248918 |
|
CLICK HERE |
| 1919 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer primario de hígado en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer primario de hígado en adultos. |
| pequeñas incisiones | 0.360209 |
| Cirujano oncólogo | 0.35403 |
| Clinic Liver Cancer | 0.895614 |
| siguientes procedimientos | 0.409083 |
| siguientes aspectos | 0.386863 |
| pequeña cantidad | 0.337477 |
| tratamiento causa | 0.413554 |
| siguientes métodos | 0.411504 |
| siguientes especialistas | 0.376622 |
| rayos x | 0.47678 |
| imagen tridimensional 3-D | 0.372363 |
| lesiones duraderas | 0.36475 |
| sustancias dañinas | 0.379531 |
| cuerpo usa | 0.466772 |
| ondas sonoras | 0.366833 |
|
| triple fase | 0.491781 |
| National Cancer Institute | 0.334891 |
| siguientes riesgos | 0.332851 |
| sección superior derecha | 0.425641 |
| Instituto Nacional | 0.432945 |
| siguientes grupos | 0.397061 |
| PDQ Tratamiento | 0.382467 |
| siguientes puntos | 0.412752 |
| estadificación barcelona clinic | 0.916026 |
| hepatitis c | 0.503388 |
| Drugs Approved | 0.34614 |
| Physician Data Query | 0.434214 |
| Barcelona Clinic Liver | 0.903635 |
| pequeña incisión | 0.343621 |
| siguientes enlaces | 0.343192 |
|
CLICK HERE |
| 2017 |
National Cancer Institute |
Html |
es |
Aspectos generales de la prevención del cáncer (PDQ®)–Versión para profesionales de salud |
Información general sobre la prevención del cáncer y descripciones de conceptos usados en sumarios específicos sobre la prevención del cáncer. |
| régimen alimentario frente | 0.52739 |
| Cancer genes | 0.521607 |
| World Cancer Research | 0.569873 |
| Iowa Women Health | 0.545115 |
| Australian Cancer | 0.523867 |
| accessed august | 0.547411 |
| Sin embargo | 0.591735 |
| American Cancer Society | 0.574381 |
| largo plazo | 0.544542 |
| radiación solar uv | 0.530547 |
| Low Levels | 0.551207 |
| Cancer Mortality Among | 0.527608 |
| Assess Health Risks | 0.519239 |
| PHS II | 0.544279 |
| Estados Unidos | 0.634682 |
| health risks from | 0.598572 |
| menor riesgo | 0.576825 |
| PDQ Prevención | 0.995577 |
| Women’s Health Study | 0.522268 |
| Cancer Epidemiology | 0.523152 |
| detección producirÃa casos | 0.524098 |
| Cancer Risk Factors | 0.532188 |
| ionizing radiation | 0.693544 |
| cancer prevention | 0.543238 |
| United States | 0.521643 |
|
| Fraumeni JF Jr | 0.580264 |
| Cancer Facts | 0.529494 |
| radiation exposure | 0.542511 |
| Radiation Protection | 0.539013 |
| vitamina b12 versus | 0.522212 |
| Health Study | 0.549664 |
| caracterÃsticas únicas | 0.524754 |
| Cancer Research | 0.60501 |
| Ionizing Radiation Exposure | 0.534695 |
| vitamina b12 | 0.53218 |
| Cancer Prevention Trial | 0.532033 |
| risks from exposure | 0.603319 |
| Clin Oncol | 0.531778 |
| vitamina b6 | 0.531978 |
| Ionizing Radiation VII | 0.531441 |
| radiación uv | 0.526208 |
| National Research Council | 0.54637 |
| Arch Intern Med | 0.544117 |
| cuello uterino | 0.588712 |
| Cancer Biol | 0.523757 |
| National Academies | 0.527165 |
| National Council | 0.522058 |
| cancer risk | 0.595574 |
| National Research | 0.546614 |
|
CLICK HERE |
| 2112 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de hígado (hepatocelular) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer hepatocelular y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| hepatitis a | 0.691582 |
| hepatitis b | 0.976325 |
| hepatitis c | 0.953816 |
| siguientes factores | 0.63541 |
| voluntarios sanos | 0.537145 |
| Physician Data Query | 0.668307 |
| Estados Unidos | 0.777756 |
| suficiente ejercicio | 0.541596 |
| prevención revisa | 0.539969 |
| sustancias dañinas | 0.552371 |
|
| PDQ Prevención | 0.566207 |
| hepatitis aguda | 0.682178 |
| cuerpo usa | 0.546831 |
| National Cancer Institute | 0.544327 |
| siguientes riesgos | 0.530546 |
| mediana edad | 0.550051 |
| siguientes sumarios | 0.587942 |
| Instituto Nacional | 0.581698 |
| múltiples funciones | 0.548976 |
|
CLICK HERE |
| 17221 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de tiroides (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar el cáncer de tiroides. |
| Thyroid Cancer Mortality | 0.4611 |
| accessed august | 0.42342 |
| anual promedio | 0.41796 |
| during first screening | 0.416166 |
| American Cancer Society | 0.461311 |
| South Korea | 0.449276 |
| Ahn HS | 0.443564 |
| Thyroid Cancer Screening | 0.461683 |
| Preventive Services Task | 0.480652 |
| Instituto Nacional | 0.427903 |
| larÃngeo recurrente causa | 0.41545 |
| PDQ Exámenes | 0.439936 |
| Estados Unidos | 0.575638 |
| Natl Cancer Inst | 0.465908 |
| Korea Community Health | 0.446353 |
| Thyroid Cancer Incidence | 0.51938 |
| US Preventive Services | 0.435857 |
| Cancer Screening Guidelines | 0.440415 |
| papillary thyroid carcinoma | 0.44378 |
| nódulos tiroideos | 0.434456 |
| SEER Cancer Statistics | 0.432375 |
| Cancer Research UK | 0.460382 |
| cohort study | 0.41948 |
| United States Preventive | 0.414458 |
| National Cancer | 0.484654 |
|
| United States | 0.420839 |
| Cancer Incidence Statistics | 0.43264 |
| thyroid cancer | 0.948734 |
| Cancer Facts | 0.42824 |
| korea's thyroid-cancer | 0.432482 |
| aumento anual promedio | 0.415042 |
| Managing incidental thyroid | 0.44237 |
| Welch HG | 0.420771 |
| Reporting Thyroid Cytopathology | 0.44067 |
| National Cancer Institute | 0.466646 |
| American College | 0.415528 |
| Sosa JA | 0.420591 |
| South Korea Thyroid-Cancer | 0.421513 |
| PDQ Tratamiento | 0.429473 |
| Kim HJ | 0.417652 |
| Community Health Survey | 0.4356 |
| Services Task Force | 0.479733 |
| Thyroid tumors | 0.437792 |
| Korea Cancer Registry | 0.440985 |
| PDQ Genetics | 0.426977 |
| Incidental Thyroid Findings | 0.439567 |
| Reino Unido | 0.431597 |
| Statistics Korea | 0.417551 |
| BMC Cancer | 0.427511 |
|
CLICK HERE |